Business
Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook
2025 net revenues increased 5.7% to $1.164 billion, compared to 2024, or 5.2% on a constant currency basis2025 net income increased to $78 million or $0.27
About this update from Sotera Health Company
[{"type":"text","content":"2025 net revenues increased 5.7% to $1.164 billion, compared to 2024, or 5.2% on a constant currency basis2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, in 20242025 Adjusted EBITDA(1) increased 8.2% to $594 million, compared to 2024, or 7.8% on a constant currency basis2025 Adjusted EPS(1) of $0.86, an increase of $0.16 per diluted share, compared to 2024Full-year 2026 outlook: net revenues growth of 5.0% to 6.5% and Adjusted EBITDA growth of 5.5% to 7.0%, on a constant currency basis CLEVELAND, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the fourth-quarter and full-year 2025 and its initial 2026 outlook. Fourth-quarter 2025 net revenues increased 4.6% to $303 million, compared to $290 million in the fourth-quarter 2024. Net revenues increased 2.5% on a constant currency basis. Net income attributable to the Company (“net income”) was $35 million, or $0.12 per diluted share, compared to net income of $12 million, or $0.04 per diluted share for the fourth-quarter 2024. Adjusted EBITDA increased by 2.7%, to $157 million, or 0.5% on a constant currency basis, compared to the fourth-quarter 2024. Fourth-quarter 2025 adjusted earnings per diluted share (“Adjusted EPS”) was $0.26, an increase of $0.05 per diluted share, compared to the fourth quarter of 2024. Full-year 2025 net revenues increased 5.7% to $1.164 billion, compared to $1.100 billion for 2024. Net revenues increased 5.2% on a constant currency basis. Net income was $78 million, or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, for 2024. Adjusted EBITDA increased 8.2% to $594 million, or 7.8% on a constant currency basis, compared to 2024. Adjusted EPS was $0.86 in 2025, an increase of $0.16 per diluted share from 2024. “The Company delivered strong results in 2025, driven by solid execution, increased demand for our mission‑critical services, and disciplined financial management,” said Michael B. Petras, Jr., Chairman and Chief Executive Officer. “Sterigenics and Nordion delivered strong performance,...